Roxadustat
http://dbpedia.org/resource/Roxadustat an entity of type: Thing
Roxadustat ist ein (HIF-PHI), der die Produktion von Hämoglobin und Erythrozyten stimuliert. Er wird als Arzneistoff zur oralen Behandlung der Anämie („Blutarmut“) infolge einer chronischen Nierenerkrankung (CKD) verwendet.
rdf:langString
Roxadustat, sold under the brand name Evrenzo, is an anti-anemia medication. Roxadustat is a HIF prolyl-hydroxylase inhibitor that increases endogenous production of erythropoietin and stimulates production of hemoglobin and red blood cells. It was investigated in clinical trials for the treatment of anemia caused by chronic kidney disease (CKD). It is taken by mouth. The drug was developed by FibroGen, in partnership with AstraZeneca.
rdf:langString
rdf:langString
Roxadustat
rdf:langString
Roxadustat
xsd:integer
55979415
xsd:integer
1119603687
rdf:langString
XA05
rdf:langString
B03
xsd:integer
19
xsd:integer
808118
xsd:integer
9431690
rdf:langString
DB04847
xsd:integer
16
xsd:integer
2
rdf:langString
D10593
rdf:langString
Rx-only
xsd:integer
2
xsd:integer
5
xsd:integer
11256664
rdf:langString
CC1=NCCNCCO
xsd:integer
1
rdf:langString
YOZBGTLTNGAVFU-UHFFFAOYSA-N
rdf:langString
FG-4592, ASP1517, AZD9941
rdf:langString
Evrenzo
rdf:langString
X3O30D9YMX
xsd:integer
250
rdf:langString
Roxadustat ist ein (HIF-PHI), der die Produktion von Hämoglobin und Erythrozyten stimuliert. Er wird als Arzneistoff zur oralen Behandlung der Anämie („Blutarmut“) infolge einer chronischen Nierenerkrankung (CKD) verwendet.
rdf:langString
Roxadustat, sold under the brand name Evrenzo, is an anti-anemia medication. Roxadustat is a HIF prolyl-hydroxylase inhibitor that increases endogenous production of erythropoietin and stimulates production of hemoglobin and red blood cells. It was investigated in clinical trials for the treatment of anemia caused by chronic kidney disease (CKD). It is taken by mouth. The drug was developed by FibroGen, in partnership with AstraZeneca. The most common side effects include hypertension (high blood pressure), vascular access thrombosis (formation of blood clots in the blood vessels associated with dialysis), diarrhea, peripheral edema (swelling especially of the ankles and feet), hyperkalemia (high blood potassium levels) and nausea (feeling sick). Roxadustat received its first global approval in China on 17 December 2018, for the treatment of anemia caused by CKD in patients who are dialysis-dependent. It was approved in Japan in 2019, for the treatment of anemia caused by CKD in patients on dialysis, and in 2020 for patients not on dialysis. Roxadustat was approved for medical use in the European Union in August 2021.
rdf:langString
Rx-only
rdf:langString
yes
xsd:nonNegativeInteger
13508
rdf:langString
Evrenzo
xsd:string
808118-40-3
xsd:string
DB04847
xsd:string
X3O30D9YMX
xsd:string
D10593
xsd:string
11256664